We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Virusight Diagnostic’s AI Solution for COVID-19 1-Second Test Demonstrates Excellent Correlation to PCR

By LabMedica International staff writers
Posted on 16 Nov 2020
Print article
Image: SpectraLIT device (Photo courtesy of Newsight Imaging Ltd.)
Image: SpectraLIT device (Photo courtesy of Newsight Imaging Ltd.)
A solution for instant COVID-19 screening from Virusight Diagnostic Ltd. (Ramat Gan, Israel) has demonstrated a high correlation to PCR in pre-clinical testing.

The pre-clinical testing included hundreds of real swab samples of COVID-19 infected and non-infected patients, taken before PCR. In this initial test, Virusight’s solution demonstrated a very high correlation to PCR while testing 130 non-labeled samples out of a total 330 samples.
The instant screening solution from Virusight, a JV of Newsight Imaging Ltd. (Ness Ziona, Israel) and the ARC Innovation Center of Sheba Medical Center (Tel HaShomer, Israel), is based on licensing of Newsight’s SpectraLIT - a game changing spectral device, together with a special AI software. The device is capable of checking a swab’s UTM liquid, or mouthwash, in only one second, using an absorbance spectrographic method.

Virusight currently has 26 active pilots with leading hospitals around the world, aiming to achieve local validation of its technology, parallel to its efforts to obtain regulation approvals. The pilots are conducted in collaboration with local partners. Alongside European countries and other areas worldwide, Virusight has already secured its distribution in Asia Pacific, signing an MOU with AI Innobio to sell 50 million tests to APAC countries to be used within one year.

“I am so excited to bring the SpectraLIT technology to the APAC region,” said Dr. George So, Chairman and acting CEO of AI InnoBio. “AI InnoBio has signed MOU with partners in eight countries in this region to introduce the “FAIR” AIIB SpectraLIT COVID-19 quick test solution for the current pandemic. We will soon start pilot studies in five countries, including India, Philippines, South Korea, Singapore, etc. AIIB SpectraLIT is “FAIR” because the technology is Fast, Affordable, Innovative and Reliable. This quick test can be used as a screening device between countries to safeguard travel bubbles and kick start economy recovery in the APAC region.”

“Virusight is in a great momentum forward,” said Eli Assoolin, Board Chairman and Acting CEO of Virusight Diagnostic. Virusight Diagnostic’s solution, powered by Newsight Imaging’s technology and Sheba Medical Center’s excellence, is about to enable affordable mass screening checks for everyone, and help the world resume normal life. We are very excited to be a part of this important goal.”

Related Links:
Virusight Diagnostic Ltd.
Newsight Imaging Ltd.
Sheba Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.